Search company, investor...

Seaside Therapeutics

seasidetherapeutics.com

Stage

Series C | Alive

Total Raised

$30M

Last Raised

$30M | 13 yrs ago

About Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development.

Headquarters Location

700 Technology Sq

Cambridge, Massachusetts, 02139,

United States

617-374-9009

Missing: Seaside Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Seaside Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Seaside Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Seaside Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Seaside Therapeutics Patents

Seaside Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/7/2013

6/2/2015

Syndromes, Rare diseases, Sedatives, Calcium channel blockers, Lactams

Grant

Application Date

6/7/2013

Grant Date

6/2/2015

Title

Related Topics

Syndromes, Rare diseases, Sedatives, Calcium channel blockers, Lactams

Status

Grant

Latest Seaside Therapeutics News

Fragile X Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Seaside Therapeutics, Novartis, Alcobra - Research and Markets

Jun 8, 2016

Fragile X Syndrome Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Seaside Therapeutics, Novartis, Alcobra - Research and Markets June 08, 2016 07:12 AM Eastern Daylight Time DUBLIN--( BUSINESS WIRE )--Research and Markets has announced the addition of the "Fragile X Syndrome Global Clinical Trials Review, H1, 2016" clinical trials to their offering. The clinical trial report, Fragile X Syndrome Global Clinical Trials Review, H1, 2016" provides an overview of Fragile X Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Fragile X Syndrome. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Scope: The report provides a snapshot of the global clinical trials landscape The report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The report provides enrollment trends for the past five years Reasons to Buy: Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned:

Seaside Therapeutics Frequently Asked Questions (FAQ)

  • Where is Seaside Therapeutics's headquarters?

    Seaside Therapeutics's headquarters is located at 700 Technology Sq, Cambridge.

  • What is Seaside Therapeutics's latest funding round?

    Seaside Therapeutics's latest funding round is Series C.

  • How much did Seaside Therapeutics raise?

    Seaside Therapeutics raised a total of $30M.

  • Who are Seaside Therapeutics's competitors?

    Competitors of Seaside Therapeutics include Epizyme, Armgo Pharma, Flexion Therapeutics, Amplyx Pharmaceuticals, Promedior and 13 more.

Compare Seaside Therapeutics to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

A
Allozyne

Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.

P
Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

A
Armgo Pharma

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.

S
Salzburg Therapeutics

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.